NCT05894759Completed
Online Therapist-guided Receptive Music Therapy in Adults With Psoriasis
Effects of Adjunctive Online Therapist-guided Receptive Music Therapy on Quality of Life and Psychological Outcomes in Adults With Psoriasis: a Three-arm Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This single-center, three-arm randomized controlled trial evaluated a four-week online therapist-guided receptive music therapy program as an adjunct to treatment as usual in adults with moderate-to-severe psoriasis and clinically relevant psychological or quality-of-life burden. Seventy-five participants were randomized in a 1:1:1 ratio to treatment as usual, treatment as usual plus an audio-based active relaxation control, or treatment as usual plus therapist-guided receptive music therapy. The principal comparison was between the music therapy and active control groups. Dermatology-specific quality of life, perceived psychological stress, anxiety, and depressive symptoms were assessed at baseline, at the end of the four-week intervention, and at three and six months after the intervention. Dermatological severity, treatment adherence, intervention adherence, and other prespecified or documented exploratory measures were also assessed. Alcohol, drugs and nicotine-use information, as well as the Revised Illness Perception Questionnaire 9, are reserved for a distinct secondary exploratory analysis and are not part of the primary efficacy evaluation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 75 (actual)
- First submitted
- 17 May 2023
- Start date
- 15 Jun 2023
- Primary completion date
- 29 Apr 2025
- Lead sponsor
- Grigore T. Popa University of Medicine and Pharmacy
- Diseases
- Psoriasis
- NCT number
- NCT05894759
What you commit to
- Study type: Interventional
- Participants enrolled: 75
- From 15 Jun 2023 to the primary completion date, 29 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Another dermatological disorder with an independent effect on quality of life.
- A clear psychiatric disorder or current psychiatric treatment.
- Major hearing impairment preventing participation in the audio interventions.
Other
- Positive response to PHQ-9 item 9, PHQ-9 functional-impact rating of 3, PHQ-9 score at least 20, or GAD-7 score at least 15.
- Current or planned participation in another clinical study that could overlap with RePSO.
- Pregnancy.
- Inability to read the study material or complete the questionnaires.
Who the study is looking for
- Age 18 years or older.
- Clinical diagnosis of moderate-to-severe psoriasis. Moderate disease was operationalized as PASI 5-10 and severe disease as PASI greater than 10; clinically severe involvement of high-impact or difficult-to-treat sites could also establish eligibility when global PASI underestimated localized burden.
- Psychological stress identified from clinical history as a trigger or aggravating factor for psoriasis and perceived-stress VAS score of at least 3.
- At least one of the following: DLQI at least 6, PHQ-9 at least 5, or GAD-7 at least 5.
- Access to a computer, laptop, or smartphone with an internet connection.
- Ability to understand the study procedures and provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Grigore T. Popa University of Medicine and Pharmacy Iasi Coordinator of this site? Confirm its status | Iași | Romania | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.